

Supplement



Supplemental Figure 1: A, Gating strategy to identify free and platelet-bound leukocytes (A, upper panel). Representative histogram depicting lower mean CD41 expression in platelets attached to leukocytes compared to those not attached (A, lower panel). **B**, Platelets stimulated with ADP (200nM) versus PBS for 30 min show higher P-selectin (CD62P) and activated GPIIb/IIIa receptor surface expressions whereas GPIIb (CD41) remains stable. Results are shown as mean±SEM; n=4 per group. *p<0.05, t-test. **C**, Mean fluorescence intensity (MFI) of CD41, and MFIs of CD62P, GPIIb/IIIa, GPV, GPVI, GPIb surface expressions normalized to the respective CD41 MFI on platelets with or without complex formation with neutrophils (PNC) or monocytes (PMC). Results are shown as mean±SEM; n=6 per group. *p<0.05 denotes statistically significant differences, one-way ANOVA, Holm-Sidak multiple

comparison test. **D**, MFI of PSGL-1, CD11a, CD11b surface expression levels on platelet-bound monocytes and neutrophils, and on unbound platelets, monocytes and neutrophils. MFI of DCFDA stained intracellular reactive oxygen species (ROS) activity in non-leukocyte bound platelets, monocytes, neutrophils, PMC and PNC. Results are shown as mean±SEM; n=6 per group. *p<0.05 denotes statistically significant differences, §p<0.05 denotes statistically significant differences with all shown groups, one-way ANOVA, Holm-Sidak's multiple comparison test.



Supplemental Figure 2: Results of blood counts from WTWT and KOWT chimeras. There were no differences in cell counts. Results are presented as mean ± SEM; n=6 per group. PLT, platelets. WBC, white blood cells/leukocytes. RBC, red blood cells/erythrocytes.

Supplemental Table 1

| Epitope | Conjugate | Clone | Manufacturer | Location |
|--------------------|----------------------|----------------|------------------|--------------------|
| CD115(c-fms) | APC | AFS98 | eBioscience | San Diego, CA, USA |
| CD11a/CD18 (LFA-1) | PerCP/Cy5.5 | H155-78 | BioLegend | San Diego, CA, USA |
| CD11b | APC/Cy7 | M1/70 | BD Pharmingen | San Jose, CA, USA |
| CD16/CD32 | - | 93 | eBioscience | San Diego, CA, USA |
| CD162 | BV421 | 2PH1 | BD Bioscience | San Jose, CA, USA |
| CD19 | PE | eBio1D3 | eBioscience | San Diego, CA, USA |
| CD31 | Pacific Blue | 390 | BioLegend | San Diego, CA, USA |
| CD41 | PE/Cy7 | MWreg30 | BioLegend | San Diego, CA, USA |
| CD42d | PerCP/Cy5.5 | 1C2 | BioLegend | San Diego, CA, USA |
| CD45.2 | eFluor450 | 104 | eBioscience | San Diego, CA, USA |
| CD45.2 | Brilliant Violet 510 | 104 | BioLegend | San Diego, CA, USA |
| CD45R/B220 | PE | RA36B2 | BD Bioscience | San Jose, CA, USA |
| CD49b | APC | ΗΜα2 | BioLegend | San Diego, CA, USA |
| CD62P | PerCP-eFlour710 | Psel.K02. 3 | eBioscience | San Diego, CA, USA |
| CD62P | BV421 | RB40.34 | BD Horizon | San Jose, CA, USA |
| F4/80 | PE/Cy7 | BM8 | BioLegend | San Diego, CA, USA |
| GPlbα (CD42b) | DyLight649 | Xia.G5 | emfret Analytics | Würzburg, Germany |
| GPIIb/IIIa | PE | JON/A | emfret Analytics | Würzburg, Germany |
| GPVI | FITC | JAQ1 | emfret Analytics | Würzburg, Germany |
| Gr-1 | PE | RB6-8C5 | BioLegend | San Diego, CA, USA |
| Ly6C | PerCP/Cy5.5 | HK1.4 | BioLegend | San Diego, CA, USA |
| Ly6C | FITC | HK1.4 | BioLegend | San Diego, CA, USA |
| Ly6G | PE | 1A8 | BD Pharmingen | San Jose, CA, USA |
| Ly6G | PE | 1A8 | BD Bioscience | San Jose, CA, USA |

Supplemental Table 2

| Gene | Assay ID |
|---------|--------------|
| TNFa | Mm00443258 |
| CCL5 | Mm01302427m1 |
| IL-6 | Mm00446190m1 |
| CCL2 | Mm00441242m1 |
| IL-1b | Mm00434226m1 |
| TGFß | Mm01178820m1 |
| IL-10 | Mm00439614m1 |
| CXCL1 | Mm04207460m1 |
| MPO | Mm01298424m1 |
| F3 | Mm00438855m1 |
| β-actin | Mm4352341Em1 |